Strategic options Selvita has announced Q1 2026 results alongside a strategic options review, indicating potential for additional partnerships, licensing discussions, or joint-venture opportunities to accelerate late-stage development and expansion of services.

Growth potential As one of Europe’s largest preclinical CROs with a mid-sized revenue range, Selvita may be receptive to scale-up collaborations, expanded outsourcing agreements, or co-development programs to broaden their portfolio and geographic reach.

Clinical-to-preclinical bridge Selvita focuses on bridging early drug discovery to clinical development, presenting opportunities to offer integrated service bundles, platform enhancements, and data-driven analytics that streamline transition phases for clients.

Digital maturity A tech stack featuring Azure, Kubernetes, Prometheus, and collaboration tools signals a readiness for modernized workflows; propose scalable cloud-enabled CRO solutions, automation, and secure data collaboration offerings.

Market positioning positioned against peers with substantial Europe presence and mid-market scale, Selvita may value competitive intelligence, regional pricing optimization, and strategic alliances to win larger multi-year contracts.